Is Clearside Biomedical, Inc. (CLSD) a Buy, Sell, or Hold?
Clearside Biomedical, Inc.
NASDAQ:CLSD
$0.41 USD
$0 (0.0%)
- Volume
- 2.05M
- Average Volume
- 264.4K
- Market Capitalization
- $2.15M
- P/E Ratio
- -0.11
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $17.10
- Year Low
- $0.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.98
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | George Lasezkay |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CLSD |
| CUSIP | 185063203 |
| CIK | 0001539029 |
| Web | https://www.clearsidebio.com |
| Phone | 678 270 3631 |
| Currency | USD |
| Employees | 32 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.98 |
| Quick Ratio | 2.98 |
| Cash Ratio | 2.46 |
Sales & Book Value
| Annual Sales | $1.66M |
| Price / Sales | 0.71 |
| Cash Flow | -3.06 |
| Price / Cash Flow | -0.13 |
| Price / Book | -0.04 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.05 |
| Trailing P/E Ratio | -0.11 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-34.35M |
| Net Margin | -618.26% |
| Pretax Margin | -594.61% |
| Return on Equity | 37.73% |
| Return on Assets | -160.55% |
Financials Score
| AltmanZ Score | -48.27 |
| Piotroski Score | 2.00 |
| Working Capital | 5.48M |
| Total Assets | 11.64M |
| Ebit | -14.7M |
| Market Cap | 2.15M |
| Total Liabilities | 65.59M |
Poll Results
About Clearside Biomedical, Inc. (NASDAQ:CLSD) Stock
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clears ... ide Biomedical, Inc. is headquartered in Alpharetta, Georgia.
2026-07-14 21:30:00
NEW YORK--(BUSINESS WIRE)--Clearside Biomedical, Inc. (“Clearside” or the “Company”) today announced that it has completed its financial restructuring and emerged from Chapter 11. All conditions to the effectiveness of the Company's plan of reorganization (the “Plan”), as confirmed by the United States Bankruptcy Court for the District of Delaware, have been satisfied or waived, and the Plan became effective on the closing date. The Plan was sponsored by Steel Partners, Ltd. (“Steel Partners”),.
Frequently Asked Questions
-
What is the current Clearside Biomedical, Inc. (CLSD) stock price?
-
Clearside Biomedical, Inc.(NASDAQ:CLSD) stock price is $0.41 in the last trading session. During the trading session, CLSD stock reached the peak price of $17.1 while $0.31 was the lowest point it dropped to. The percentage change in CLSD stock occurred in the recent session was 0.0% while the dollar amount for the price change in CLSD stock was $0.
-
CLSD's industry and sector of operation?
-
The NASDAQ listed CLSD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLSD?
-
Charles A. Deignan | Principal Financial Officer & Principal Accounting Officer
George Lasezkay | Director & Principal Executive Officer
Rafael V. Andino | Senior Vice President of Engineering & Manufacturing
Rick McElheny | Senior Vice President of Corporate Development & Alliance Management
Jenny R. Kobin | Head of Investor Relations -
How many employees does CLSD have?
-
Number of CLSD employees currently stands at 32. CLSD operates from 900 North Point Parkway, Alpharetta, GA 30005, US.
-
Link for CLSD official website?
-
Official Website of CLSD is: https://www.clearsidebio.com
-
How do I contact CLSD?
-
CLSD could be contacted at phone #678 270 3631 and can also be accessed through its website. CLSD operates from 900 North Point Parkway, Alpharetta, GA 30005, US.
-
How many shares of CLSD are traded daily?
-
The average number of CLSD shares traded daily for last 3 months was 264.4K.
-
What is the market cap of CLSD currently?
-
The market value of CLSD currently stands at $2.15M with its latest stock price at $0.41